SPRO
SPRO
NASDAQ · Biotechnology

Spero Therapeutics Inc

$1.26
-0.01 (-0.79%)
As of Aug 15, 2:14 AM ET ·
Financial Highlights (FY 2026)
Revenue
64.74M
Net Income
8.31M
Gross Margin
Profit Margin
12.8%
Rev Growth
+7.7%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 49.6% 49.6%
Operating Margin 9.4% 8.5% -22.5% -21.2%
Profit Margin 12.8% 12.2% -19.0% -18.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 64.74M 60.12M 30.93M 26.54M
Gross Profit 15.33M 13.15M
Operating Income 6.12M 5.11M -6,967,592 -5,637,171
Net Income 8.31M 6.94M -5,880,957 -4,950,304
Gross Margin 49.6% 49.6%
Operating Margin 9.4% 8.5% -22.5% -21.2%
Profit Margin 12.8% 12.2% -19.0% -18.7%
Rev Growth +7.7% +7.7% +18.4% +23.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 26.75M 29.13M
Total Equity 80.40M 90.84M
D/E Ratio 0.33 0.32
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 6.12M 5.40M -8,827,347 -7,842,890
Free Cash Flow -6,633,459 -6,096,996